Loading…
Sinopharm-group pharma distributor and manufacturer serving Guangdong and South China's hospitals and pharmacies.
Sinopharm-group pharma distributor and manufacturer serving Guangdong and South China's hospitals and pharmacies.
Earns a small margin on each drug it buys from manufacturers and delivers to hospitals and pharmacies, so revenue is large relative to profit. Sinopharm, the state-owned national drug distributor, is its controlling shareholder.
In one line: A regional McKesson with a small factory arm.
Moat: narrow (scale, distribution). Dense South China distribution network under state-owned Sinopharm's national logistics umbrella.
Headquarters: Shenzhen, China · Employees: 28,336
Size China National Accord Medicines (000028.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.85B, the 1361st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥21.50 on 6 Nov 2026.
Performance Over six months the shares fell 3.6%, against -9.3% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 0.4% over the last twelve months (peer median +12.3%); the operating margin is 2.3% (peer median 19.4%).
Valuation It trades at 11.1× forward earnings against a peer median of 24.4× (3rd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥73.4B | CN¥73.3B | CN¥74.3B | CN¥75.4B | CN¥73.3B |
| Revenue growth | — | -1% | -1% | +3% | — |
| Gross profit | CN¥7.68B | CN¥6.36B | CN¥6.46B | CN¥7.40B | CN¥7.38B |
| EBITDA | n/a | CN¥3.14B | CN¥3.25B | CN¥3.92B | CN¥3.79B |
| Net income | CN¥1.13B | CN¥1.14B | CN¥642M | CN¥1.60B | CN¥1.49B |
| Free cash flow | CN¥1.50B | CN¥1.52B | CN¥3.18B | CN¥2.85B | CN¥2.21B |
| Capital expenditure | CN¥139M | CN¥217M | CN¥283M | CN¥322M | CN¥322M |
| Total debt | CN¥12.0B | CN¥14.7B | CN¥14.3B | CN¥13.8B | CN¥10.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China National Accord Medicines 000028.SZ | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% |
| China Resources Pharmaceutical 3320.HK | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% |
| Shanghai Pharmaceuticals 601607.SS | $8.32B | -2% | +4% | 3% | 11.4× | -10.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000028.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.9% | -2.7% | 4th highest of 21 |
| 6-month return | -3.6% | -9.3% | 10th highest of 21 |
| Distance from 52-week high | -13.8% | -27.8% | 2nd highest of 21 |
| Revenue growth (TTM) | +0.4% | +12.3% | 4th lowest of 21 |
| Operating margin | 2.3% | 19.4% | 4th lowest of 21 |
| Forward P/E | 11.1× | 24.4× | 3rd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -9.4% | 11.5% | 3rd least demanding of 15 |
| Growth delivered (Del g) | +4.2% | +13.2% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | -13.6 pp | +1.7 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +1.4 pp | +0.4 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% | +4.2% |
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% | +7.4% |
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% | +2.4% |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 25.7× | 24.7% | +20.9% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.88B | -13% | -6% | 8% | 22.5× | 0.1% | +0.5% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 10.1× | n/a | n/a |
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | n/a | n/a | n/a |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 12.4× | -14.2% | +37.6% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 27.8× | 19.5% | +10.8% |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |